1-4 of 4
Magdalena Piotrowska
Close
Sort by
Journal Articles

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Tadeusz Robak, Jerzy Z. Blonski, MD, PhD, Krzysztof Jamroziak, MD, PhD, Aleksander Skotnicki, Professor, Magdalena Piotrowska, MD, Anatoly Uss, Professor, Janusz Kloczko, Professor, Jaroslaw Piszcz, Kazimierz Kuliczkowski, Professor, Tomasz Wrobel, MD PhD, Bozena Katarzyna Budziszewska, MD, PhD, Marta Fidecka, Piotr Smolewski, Professor
Journal: Blood
Blood (2013) 122 (21): 1640.
https://doi.org/10.1182/blood.V122.21.1640.1640
Published: 2013
Journal Articles

Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Krzysztof Jamroziak, Janusz Szemraj, PhD, Andy Rawstron, PhD, Zofia Szemraj-Rogucka, MD, Olga Grzybowska-Izydorczyk, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Gabriele Buda, M.D., PhD, Alessandro Martino, PhD, Dorota Jesionek-Kupnicka, MD, PhD, Ida Franiak-Pietryga, PhD, Magdalena Piotrowska, MD, Tadeusz Robak, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4585.
https://doi.org/10.1182/blood.V118.21.4585.4585
Published: 2011
Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Anders OĢˆsterborg, Birgitte Biilmann Ronn, Roxanne C Jewell, Thomas J Kipps, Jiri Mayer, Stephan Stilgenbauer, Cathy D Williams, Andrzej Hellmann, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny, Martin JS Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Michael Arning, Nedjad Losic, Randy Davis, Joris Wilms, Charlotte A Russell, William G Wierda
Journal: Blood
Blood (2009) 114 (22): 3433.
https://doi.org/10.1182/blood.V114.22.3433.3433
Published: 2009
Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Anders Osterborg, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, Stephan Stilgenbauer, Dr.med, Catherine D Williams, MBBS, MRCP, FRCPath, Andrzej Hellmen, MD, PhD, Tadeusz Robak, MD, PhD, Richard R Furman, MD, Peter Hillmen, MBChB, PhD, Marek Trneny, MD, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Swaminathan Padmanabhan, MD, MBBS, Tomas Kozak, MD, PhD, Geoffrey Chan, MD, Randy L Davis, DrPH, Nedjad Losic, MSc, Charlotte A. Russell, MD, DMSC, Magdalena Piotrowska, MD, Joris Wilms, MSc., Pharm, William G. Wierda, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 328.
https://doi.org/10.1182/blood.V112.11.328.328
Published: 2008